Page last updated: 2024-10-25

chlorzoxazone and Hematologic Malignancies

chlorzoxazone has been researched along with Hematologic Malignancies in 1 studies

Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.

Research Excerpts

ExcerptRelevanceReference
"Benzene is a ubiquitous occupational hematotoxin and leukemogen, but people vary in their response to this toxic agent."1.30Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. ( Campleman, S; Dosemeci, M; Hayes, RB; Hoener, B; Li, GL; Linet, M; Lu, W; Meyer, KB; Ross, D; Rothman, N; Smith, MT; Stewart, JT; Titenko-Holland, N; Traver, RD; Wacholder, S; Xi, L; Yin, S; Zhang, L, 1997)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rothman, N1
Smith, MT1
Hayes, RB1
Traver, RD1
Hoener, B1
Campleman, S1
Li, GL1
Dosemeci, M1
Linet, M1
Zhang, L1
Xi, L1
Wacholder, S1
Lu, W1
Meyer, KB1
Titenko-Holland, N1
Stewart, JT1
Yin, S1
Ross, D1

Other Studies

1 other study available for chlorzoxazone and Hematologic Malignancies

ArticleYear
Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone.
    Cancer research, 1997, Jul-15, Volume: 57, Issue:14

    Topics: Benzene; Chlorzoxazone; Cohort Studies; Cytochrome P-450 CYP2E1; Hematologic Neoplasms; Humans; Muta

1997